Vanda CEO: FDA Communication Key to Non-Preagreed Endpoints

Drug Industry Daily
A A
Despite not agreeing on primary endpoints with the FDA before beginning clinical trials for a new sleep disorder drug, Vanda was able to get an almost unanimous recommendation from an advisory committee earlier this month.

To View This Article:

Login

Subscribe To Drug Industry Daily